Screener
TG Therapeutics TGTX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | $1,035,546 | $415,233 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 159,949,330 and 158,849,596 shares issued, 153,077,784 and 155,305,953 shares outstanding at June 30, 2026 and December 31, 2025, respectively) | 160 | 159 |
| Additional paid-in capital | 1,858,606 | 1,830,110 |
| Treasury stock, at cost, 6,871,546 and 3,543,643 shares at June 30, 2026 and December 31, 2025, respectively | (200,226) | (100,234) |
| Accumulated deficit | (1,054,457) | (1,082,015) |
| Total stockholders’ equity | 604,083 | 648,020 |
Document
FAQ
- What is TG Therapeutics's common stock?
- TG Therapeutics (TGTX) reported common stock of $160K in Q2 2026.
- How has TG Therapeutics's common stock changed year-over-year?
- TG Therapeutics's common stock increased by 0.6% year-over-year, from $159K to $160K.
- What is the long-term trend for TG Therapeutics's common stock?
- Over 5 years (2020 to 2025), TG Therapeutics's common stock has grown at a 2.4% compound annual growth rate (CAGR), from $141K to $159K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about TG Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude